Log in to search using one of your social media accounts:

 

5 ways to optimize CT lung cancer screening

An academic hospital that implemented a CT lung cancer screening program obtained...Read more on AuntMinnie.comRelated Reading: Stricter CT lung screening criteria deal mixed results Cancer deaths continue to fall, but CT lung screening lags Risk-based lung cancer screening tops USPSTF guidelines Chest doctors issue guidelines for CT lung cancer screening Canadian risk model boosts CT lung screening efficiency
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news

Related Links:

Condition:   Lung Cancer Intervention:   Device: CPAP Sponsor:   Mark M. Fuster, MD Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
CONCLUSIONS The constructed siRNA expression vectors can effectively suppress the expression of HIF-2α and P-gp, which then can reverse the chemotherapy resistance of A549 cells. PMID: 29469087 [PubMed - in process]
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research
As lung cancer screening is a relatively new area, particularly to non-healthcare professionals, understanding of the procedure and risks involved are generally not well understood. Here, Mamta Rupare... Author: VJOncology Added: 02/23/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
Conclusions: The establishment of a low-dose CT lung cancer screening program improved the ability to screen patients as demonstrated by the number of patients screened and those diagnosed with a malignancy. These findings were also consistent with the findings from the National Lung Screening Trial study.
Source: American Journal of Clinical Oncology - Category: Cancer & Oncology Tags: Original Articles: Health Policy Source Type: research
This study sought to determine changes in practice patterns for treatment of stage IA non–small cell lung cancer (NSCLC) after the introduction of SABR into the United States. This population-based study also examined changes in survival during this time period for all patients and specifically for patients treated with RT, surgery, or observation. Methods: We included patients in the Surveillance, Epidemiology, and End Results database diagnosed with stage IA NSCLC diagnosed between 2004 and 2012. Changes in treatment patterns were assessed. Outcomes were compared across 2 time periods: 2004 to 2008 (pre-SABR) an...
Source: American Journal of Clinical Oncology - Category: Cancer & Oncology Tags: Original Articles: Thoracic Source Type: research
In spite of the growing body of data from prospective randomized clinical trials (PRCTs) and meta-analyses, the optimal treatment approach in patients with stage IIIA non–small cell lung cancer remains unknown. This review focuses on the available data directly confronting induction chemotherapy or induction radiochemotherapy (RT-CHT) when followed by surgery with exclusive RT-CHT. Seven PRCTs and 4 meta-analyses investigated this issue. In addition, numerous retrospective studies attempted to identify potential predictors and/or prognosticators that may have influenced the decision to offer surgery in a particular p...
Source: American Journal of Clinical Oncology - Category: Cancer & Oncology Tags: Review Article: Thoracic Source Type: research
Authors: Re MD, Rofi E, Restante G, Crucitta S, Arrigoni E, Fogli S, Maio MD, Petrini I, Danesi R Abstract Rationale: KRAS is the most common and, simultaneously, the most ambiguous oncogene implicated in human cancer. Despite KRAS mutations were identified in Non Small Cell Lung Cancers (NSCLCs) more than 20 years ago, selective and specific inhibitors aimed at directly abrogating KRAS activity are not yet available. Nevertheless, many therapeutic approaches have been developed potentially useful to treat NSCLC patients mutated for KRAS and refractory to both standard chemotherapy and targeted therapies.The focus ...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Authors: Ezoe Y, Mizusawa J, Katayama H, Kataoka K, Muto M Abstract Background: Hyponatremia is a common electrolyte abnormality in cancer patients who receive chemotherapy. Among anticancer agents, platinum-based agents are reported to cause chemotherapy-induced hyponatremia. However, the actual incidence and risk factors remain unknown. Results: The reports of 29 trials were analyzed. The incidence of grade 3/4 hyponatremia was 11.9% in patients treated with platinum-based chemotherapy and 3.8% in those treated with nonplatinum-based regimens (P
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Authors: Thakur C, Rapp UR, Rudel T Abstract Identifying metastatic tumor growth at an early stage has been one of the biggest challenges in the treatment of lung cancer. By genetic lineage tracing approach in a conditional model of Non-Small Cell Lung Cancer (NSCLC) in mice, we demonstrate that cystic lesions represent an early stage of metastatic invasion. We generated a mouse model for NSCLC which incorporated a heritable DsRed fluorescent tag driven by the ubiquitous CAG promoter in the alveolar type II cells of the lung. We found early cystic lesions in a secondary organ (liver) that lacked the expression of b...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
In conclusion, the specific determination of C4d may serve as an adjunct to current clinical practice in the diagnosis of indeterminate pulmonary nodules. PMID: 29464077 [PubMed]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
More News: Academia | Canada Health | Cancer | Cancer & Oncology | Hospitals | Lung Cancer